

# Pinbo Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2965477/publications.pdf>

Version: 2024-02-01

15  
papers

449  
citations

759233

12  
h-index

940533

16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

873  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2017, 77, 2255-2265.	0.9	166
2	ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 18.	8.6	34
3	Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway. <i>Cancer Management and Research</i> , 2018, Volume 10, 6339-6355.	1.9	30
4	Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 79-86.	2.1	30
5	Diagnostic performance of ultrasonography, dual-phase 99mTc-MIBI scintigraphy, early and delayed 99mTc-MIBI SPECT/CT in preoperative parathyroid gland localization in secondary hyperparathyroidism. <i>BMC Medical Imaging</i> , 2020, 20, 91.	2.7	24
6	Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression. <i>Oncogene</i> , 2021, 40, 28-45.	5.9	22
7	The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. <i>Clinica Chimica Acta</i> , 2018, 480, 186-192.	1.1	21
8	Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: <i>Ex Vivo</i> Culture Evidence. <i>Clinical Cancer Research</i> , 2015, 21, 4420-4430.	7.0	18
9	&lt;p&gt;Development and external validation of prognostic nomograms in hepatocellular carcinoma patients: a population based study&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2691-2708.	1.9	17
10	Expression of CCN family members correlates with the clinical features of hepatocellular carcinoma. <i>Oncology Reports</i> , 2015, 33, 1481-1492.	2.6	16
11	SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters. <i>Cell Death and Disease</i> , 2021, 12, 731.	6.3	14
12	Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection. <i>International Journal of Surgery</i> , 2017, 48, 23-31.	2.7	13
13	Advanced glycosylation end product promotes forkhead box O1 and inhibits Wnt pathway to suppress capacities of epidermal stem cells. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 5569-5579.	0.0	7
14	Nanocomplexation of thrombin with cationic amylose derivative for improved stability and&nbsp;hemostatic efficacy. <i>International Journal of Nanomedicine</i> , 2015, 10, 939.	6.7	4
15	Ropivacaine via nuclear factor kappa B signalling modulates CD62E expression and diminishes tumour cell arrest. <i>Journal of Anesthesia</i> , 2019, 33, 685-693.	1.7	3